References
- Soulages A, Sibon I, Vallat JM, et al. Neurologic manifestations of giant cell arteritis. J Neurol. 2022;269(7):3430–3442. doi:10.1007/s00415-022-10991-6.
- McDonnell PJ, Moore GW, Miller NR, Hutchins GM, Green WR. Temporal arteritis. A clinicopathologic study. Ophthalmology. 1986;93(4):518–530. doi:10.1016/S0161-6420(86)33706-0.
- ter Borg EJ, Haanen HC, Seldenrijk CA. Relationship between histological subtypes and clinical characteristics at presentation and outcome in biopsy-proven temporal arteritis. identification of a relatively benign subgroup. Clin Rheumatol. 2007;26(4):529–532. doi:10.1007/s10067-006-0332-0.
- Lee YC, Padera RF, Noss EH, et al. Clinical course and management of a consecutive series of patients with “healed temporal arteritis”. J Rheumatol. 2012;39(2):295–302. doi:10.3899/jrheum.110317.
- Salter M, Chacko J, Stanley J, Henry W, Brown H. The clinical characteristics, treatment, and outcomes of giant cell arteritis are dependent on histological subtype. Int J Ophthalmic Patho. 2018;7:1. doi:10.4172/2324-8599.100214.
- Gruener AM, Poostchi A, Carey AR, et al. Association of giant cell arteritis with race. JAMA Ophthalmol. 2019;137(10):1175–1179. doi:10.1001/jamaophthalmol.2019.2919.
- Hayreh SS, Podhajsky PA, Raman R, Zimmerman B. Giant cell arteritis: validity and reliability of various diagnostic criteria. Am J Ophthalmol. 1997;123(3):285–296. doi:10.1016/S0002-9394(14)70123-0.
- Ing EB, Lahaie Luna G, Toren A, et al. Multivariable prediction model for suspected giant cell arteritis: development and validation. Clin Ophthalmol. 2017;11:2031–2042. doi:10.2147/OPTH.S151385.
- R Core Team. R: a language and environment for statistical computing. R foundation for statistical computing. Vienna, Austria. 2021. https://Www.R-project.org/.
- Albert DM, Ruchman MC, Keltner JL. Skip areas in temporal arteritis. Arch Ophthalmol. 1976;94(12):2072–2077. doi:10.1001/archopht.1976.03910040732006.
- Durling B, Toren A, Patel V, Gilberg S, Weis E, Jordan D. Incidence of discordant temporal artery biopsy in the diagnosis of giant cell arteritis. Can J Ophthalmol. 2014;49(2):157–161. doi:10.1016/j.jcjo.2013.12.008.
- Stacy RC, Rizzo JF, Cestari DM. Subtleties in the histopathology of giant cell arteritis. Semin Ophthalmol. 2011;26(4–5):342–348. doi:10.3109/08820538.2011.588656.
- Allison MC, Gallagher PJ. Temporal artery biopsy and corticosteroid treatment. Ann Rheum Dis. 1984 Jun;43(3):416–417. doi:10.1136/ard.43.3.416.
- Jakobsson K, Jacobsson L, Mohammad AJ, et al. The effect of clinical features and glucocorticoids on biopsy findings in giant cell arteritis. BMC Musculoskelet Disord. Aug 24 2016;17(1):363. doi:10.1186/s12891-016-1225-2.
- Narváez J, Bernad B, Roig-Vilaseca D, et al. Influence of previous corticosteroid therapy on temporal artery biopsy yield in giant cell arteritis. Semin Arthritis Rheum. Aug 2007;37(1):13–19. doi:10.1016/j.semarthrit.2006.12.005.
- González-López JJ, González-Moraleja J, Burdaspal-Moratilla A, et al. Factors associated to temporal artery biopsy result in suspects of giant cell arteritis: a retrospective, multicenter, case-control study. Acta Ophthalmol. Dec 2013;91(8):763–768. doi:10.1111/j.1755-3768.2012.02505.x.